A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-09-15

Target enrollment:

Participant gender:

The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.

PHASE2

AbbVie

AstraZeneca